Angioedema Caused by Drugs That Prevent the Degradation of Vasoactive Peptides: A Pharmacovigilance Database Study
Angioedema results from the decreased degradation of vasoactive peptides such as substance P and bradykinin. In this study, we sought to clarify whether dipeptidyl peptidase-4 (DPP-4) and angiotensin-converting enzyme (ACE) inhibitors that suppress the degradation of substance P and bradykinin are i...
Main Authors: | Yoshihiro Noguchi, Azusa Murayama, Hiroki Esaki, Mayuko Sugioka, Aisa Koyama, Tomoya Tachi, Hitomi Teramachi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/23/5507 |
Similar Items
-
Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01) -
Teneligliptin in management of type 2 diabetes mellitus
by: Sharma SK, et al.
Published: (2016-08-01) -
Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
by: Ágnes Kinyó, et al.
Published: (2021-04-01) -
Saxagliptin for type 2 diabetes
by: Chacra
Published: (2010-09-01) -
Ocular cicatricial pemphigoid following Dipeptidyl Peptidase-4 inhibitor use: A case report
by: Akifumi Matsumoto, et al.
Published: (2023-12-01)